Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃

Introduction/Overview

Asarylaldehyde (CAS No.: 4460-86-0) is a natural carbonyl compound with significant biological activity, attracting widespread attention in the field of natural product pharmacology due to its potential for various pharmacological effects. As a natural COX-2 inhibitor, octanal specifically inhibits cyclooxygenase II (COX-2) activity, demonstrating potential value in anti-inflammatory and related disease treatment. In recent years, with in-depth research into the molecular mechanisms of complex diseases such as pulmonary hypertension (PH), octanal has been regarded as a potential therapeutic candidate due to its regulatory ability to control multiple key targets.

This paper aims to systematically review the chemical structure and physicochemical properties of octanal, plant origins and extraction methods, pharmacological activity and mechanism of action, druggability evaluation, and pharmacokinetic characteristics, with a focus on its molecular targets and therapeutic prospects in diseases such as pulmonary arterial hypertension, providing a theoretical foundation and research direction for subsequent drug development and clinical translation.

Chemical structure and physicochemical properties

Acantal is a typical carbonyl compound with a molecular formula of C_10H_12O_3 and a molecular weight of 196.20. Its structure contains an aldehyde group (-CHO) and an aromatic ring, giving it specific chemical and biological reactivity. In terms of physicochemical properties, the LogP value of octanal is 1.3, indicating moderate lipid solubility, which is beneficial for cell membrane penetration and bioavailability. Its topological pole surface area (TPSA) is 55.38 Ų, and it has 4 hydrogen bond acceptors, suggesting certain hydrophilicity and binding potential in intermolecular interactions.

Aoctanal has a relatively low blood-brain barrier penetration (BBB), which may limit its application in central nervous system diseases but also reduces the risk of central toxicity. Toxicological evaluations showed that octanal had no significant hepatotoxicity or cardiotoxicity, and did not inhibit hERG channels, reducing the potential risk of arrhythmias. The results of Ames-induced mutagenic tests are still unclear, indicating the need for further genotoxicity safety evaluation.

Plant Origins and Extraction Methods

Asarum spp. is mainly found in Asarum plants, especially in the volatile oils and extracts of the medicinal herb Asarum spp. As a traditional Chinese medicine, Asarum is widely used in the treatment of rheumatic pain, headaches, and respiratory diseases. One of its pharmacological active components is Asarum.

Common methods for extracting octanal include steam distillation, solvent extraction, and supercritical CO_2 extraction. Steam distillation is suitable for extracting Asarum volatile oil, but its purity is relatively low and requires subsequent separation and purification. Solvent extraction mostly uses ethanol or methanol, combined with liquid chromatography (HPLC) or gas chromatography-mass spectrometry (GC-MS) for component analysis and purity control. Supercritical CO_2 extraction has gradually become the preferred technology for extracting octanal due to its strong selectivity and environmental friendliness.

In recent years, with the development of green extraction technologies, ultrasound-assisted and microwave-assisted extraction have also been applied to the efficient extraction of aoctanal, significantly improving yield and purity, and providing technical support for industrial production.

Pharmacological activity research

The pharmacological activity of acanal is mainly reflected in its anti-inflammatory, antioxidant, and vascular function regulation. As a COX-2 inhibitor, octanal can significantly suppress cyclooxygenase II activity by IC_50 about 100 μg/mL, demonstrating moderate selective inhibition. As a key enzyme in inflammatory responses, COX-2's inhibition helps alleviate inflammation and related pathological processes.

In animal models of pulmonary hypertension, octanal improves pulmonary vascular remodeling and hemodynamic abnormalities by modulating multiple molecular targets. Related studies show that the targets affected by acanal include ABCB1 (ATP-binding cassette transporter protein B1), CA12 (carbonic anhydrase 12), HMGCR (3-hydroxy-3-methylglutaryl-CoA reductase), ACE (acetylcholinesterase), ERN1 (endoplasmic reticulum stress sensor), KCNA5 (voltage-gated potassium channel), TGFB1 (transforming growth factor β1), NOS3 (endothelial nitric oxide synthase), CACNA1C (L-type calcium channels) and AGTR1 (angiotensin II receptor 1), among others. These targets play important roles in the pathogenesis of pulmonary arterial hypertension, and the multi-target regulatory properties of octanal provide a molecular basis for its therapeutic potential.

In addition, octanal exhibits certain antioxidant activity, which can eliminate free radicals, reduce oxidative stress damage to vascular endothelium, and further promote the recovery of vascular function.

Mechanism of action and molecular targets

The mechanisms of action of aoctanal are complex and diverse, mainly achieving its pharmacological effects through the following aspects:

1. COX-2 inhibitory effect
   Aoctanal binds to the active site of COX-2 enzyme, inhibiting its catalytic prostaglandin synthesis, reducing the production of inflammatory mediators, and alleviating inflammatory responses. Its IC_50 is 100 μg/mL, showing strong enzyme inhibitory activity.

2. Regulation of targets related to pulmonary arterial hypertension

3. ABCB1: Acts as an exotic drug pump, regulating intracellular drug concentrations. Octanal may influence drug metabolism and cellular protection mechanisms by modulating ABCB1 expression.
4. CA12: Involved in acid-base balance and intracellular environmental regulation, octanal's regulation of CA12 helps improve pulmonary arterial endothelial function.
5. HMGCR: a rate-limiting enzyme for cholesterol synthesis. Aoctanal may regulate lipid metabolism by inhibiting HMGCR, thereby alleviating vascular lesions.
6. ACHE: Regulates the degradation of the neurotransmitter acetylcholine, affecting vascular tone and neural regulation.
7. ERN1: Endoplasmic reticulum stress sensor. Acanalal reduces cellular stress responses by regulating ERN1 and protects pulmonary vascular cells.
8. KCNA5 and CACNA1C: regulate the function of potassium and calcium channels; octanal modulates the contraction state of vascular smooth muscle cells by affecting these channels.
9. TGFB1: Regulates cell proliferation and fibrosis; octanal inhibits the TGFB1 signaling pathway and alleviates pulmonary vascular remodeling.
10. NOS3: Promotes nitric oxide production and vasodilation; octanal improves vasodilation by activating NOS3.

11. AGTR1: Angiotensin II receptor, regulates vasoconstriction and blood pressure. Octanal antagonizes AGTR1 and helps lower pulmonary artery pressure.

12. Antioxidant and anti-fibrotic effects
    Aoctanal reduces oxidative stress damage by scavenging reactive oxygen species (ROS) and regulating antioxidant enzyme systems. At the same time, it suppresses the expression of fibrosis-related factors and prevents pathological thickening of the pulmonary artery wall.

In summary, octanal leverages its potential in treating pulmonary arterial hypertension and related diseases through synergistic action across multiple targets and pathways.

Druggability evaluation and pharmacokinetics

The druggability parameters of aoctanal indicate that it has good potential for drug development. The molecular weight is 196.2, meeting the Lipinski rule molecular weight requirements; the LogP value is 1.3, indicating moderate lipid solubility, which is beneficial for drug absorption and distribution. TPSA was 55.38 Ų, indicating good membrane penetration capability.

In terms of safety, octanal is non-hepatotoxic and cardiotoxic, and does not inhibit hERG channels, reducing the risk of adverse cardiovascular reactions. The blood-brain barrier penetration capacity is relatively low, which may limit its application in the central nervous system, but it is beneficial for peripheral targeted therapy.

Pharmacokinetic research is still in its early stages. Current data indicate that octanal is well absorbed orally, metabolism in the body is mainly carried out through hepatic enzyme systems, and the metabolites are safe. Future research on in vivo pharmacokinetics (ADME) of octanal, including bioavailability, half-life, tissue distribution, and excretion pathways, is needed to guide clinical formulation design and administration regimen optimization.

Prospects and outlooks for clinical applications

As a natural COX-2 inhibitor, octanal combines its multi-target regulatory effect on pulmonary arterial hypertension, showing broad clinical application prospects. Pulmonary hypertension is a serious cardiopulmonary disease characterized by increased pulmonary artery pressure and vascular remodeling. Existing treatments are limited and have significant side effects. The multi-target mechanism of acanal provides a new approach for the comprehensive treatment of pulmonary arterial hypertension.

Additionally, the anti-inflammatory, antioxidant, and anti-fibrotic properties of aoctanal may enable it to have potential therapeutic effects in other inflammatory diseases, cardiovascular diseases, and metabolic syndromes. Future research should focus on preclinical safety evaluation, pharmacodynamic validation, and clinical trial design of asoctanal to promote its clinical application.

At the same time, based on the structural characteristics and mechanisms of action of acanal, chemical modification and drug design optimization also warrant in-depth exploration to enhance its bioactivity and pharmacokinetic properties, and to develop derivatives with greater clinical value.

Conclusion

As a naturally derived carbonyl compound, octanal demonstrates excellent pharmacological activity and drug potential due to its significant COX-2 inhibitory activity and multi-target regulation of pulmonary arterial hypertension. Its moderate physicochemical properties and excellent safety profile lay the foundation for its role as a candidate molecule for novel natural medicines.

In the future, by combining modern pharmacology, molecular biology, and medicinal chemistry techniques, in-depth elucidation of the mechanism of action and pharmacokinetic characteristics of octanal will help advance its clinical application. Aoctanal not only provides an important example for pharmacological research of natural products, but also brings new hope for the treatment of complex diseases such as pulmonary hypertension.